Related Experiment Video
Updated: Feb 5, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Antibody-drug conjugates in triple negative breast cancer
Nancy Tray1, Sylvia Adams1, Francisco J Esteva1
1Perlmutter Cancer Center at New York University Langone Health, New York, NY 10016, USA.
Abstract:
Triple negative breast cancer (TNBC) is a heterogeneous disease that comprises 15-20% of all breast cancers and is more frequently seen in younger women, African-Americans, and BRCA1 expression. Advanced TNBC carries aggressive features and is associated with overall poor outcomes. Unfortunately, there are no targeted therapies available for non-BRCA associated TNBC, which remains a high unmet therapeutic need. One emerging treatment modality includes antibody-drug conjugates which are highly selective monoclonal antibodies conjugated to cytotoxic agents, designed to deliver cytotoxic drugs to antigen-expressing tumor cells. This review will highlight three antibody-drug conjugates currently being evaluated in TNBC (CDX-011, SGN-LIV1a, IMMU-132), including one that has been given Breakthrough Therapy designation from the US FDA.
Insights
Triple negative breast cancer (TNBC) is an aggressive disease lacking targeted therapies. Antibody-drug conjugates offer a promising new treatment approach by delivering cytotoxic agents directly to tumor cells.
Area of Science:
- Oncology
- Pharmacology
Background:
- Triple negative breast cancer (TNBC) accounts for 15-20% of breast cancers, often presenting aggressively in younger women and specific demographics.
- Advanced TNBC is associated with poor prognosis and a significant unmet therapeutic need due to the absence of targeted therapies for non-BRCA subtypes.
Purpose of the Study:
- To review emerging antibody-drug conjugate (ADC) therapies for triple negative breast cancer.
- To highlight specific ADCs under evaluation for TNBC treatment.
Main Methods:
- Literature review of current research on antibody-drug conjugates in TNBC.
- Focus on ADCs targeting specific antigens on TNBC cells.
Main Results:
- Identified three key ADCs (CDX-011, SGN-LIV1a, IMMU-132) being evaluated in TNBC clinical trials.
- Noted that one ADC has received US FDA Breakthrough Therapy designation.
Conclusions:
- Antibody-drug conjugates represent a promising therapeutic strategy for TNBC.
- Further investigation and clinical evaluation of these ADCs are warranted to address the unmet need in TNBC treatment.
Related Concept Videos
02:50Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
02:50Conjugated Proteins
01:19Conjugation
02:29Relative Strengths of Conjugate Acid-Base Pairs
01:06Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
01:23Negative Regulator Molecules